Meeting
2021 Gastrointestinal Cancers Symposium
Targeted therapies in cholangiocarcinoma: Assessment of US oncologist practice patterns.
Authors
Kinjal Parikh
Medscape Oncology, New York, NY
Kinjal Parikh , Davecia Ragoonath Cameron , Tristin Abair , Patrick Kugel , Arndt Vogel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Other
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 347)
DOI
10.1200/JCO.2021.39.3_suppl.347
Abstract #
347
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.
First Author: Ian M. Silverman
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world use of pemigatinib (pemi) for cholangiocarcinoma (CCA) among racial and ethnic minorities in the United States.
First Author: Richard D. Kim
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Incidence and prognostic value of actionable mutations in early-stage resectable cholangiocarcinoma.
First Author: Kailey Morgan Oppat
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Longitudinal trends in health-related quality of life (HRQoL) among patients treated with ivosidenib (IVO) for IDH1-mutated cholangiocarcinoma (CCA) in the ClarIDHy study.
First Author: Christina X. Chamberlain